We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
1. Carmell is addressing the burden of healing with its proprietary Plasma-based Bioactive Materials (PBM) technology
a. Carmell is focused on improving patients’ quality of life and reducing costs to the healthcare system
b. Clear FDA regulatory pathway supported by 16+ patent estate
c. Led by strong and seasoned management team backed with category experience in developing and commercializing drug/biologic/drug combination products at leading international pharmaceutical and device companies.
Carmell is employing a rigorous FDA pathway with a Biologic License Application, giving the company the credibility of an FDA-vetted process
Defined BLA pathway provides opportunity with hospital Value Analysis Committees (VACs), who seek proof of efficacy and safety, as well as with potential partners who seek differentiation
Carmell’s novel plasma-based technology is uniquely suited for multiple, high-value indications